Thursday, January 15

Healthcare

J&J Rybrevant/Lazcluze study shows superiority over Tagrisso

09/10/20241 Min Read

JampJ RybrevantLazcluze shows study superiority Tagrisso

Previous ArticleSummit a ‘top pick’ at Citi after ‘unprecedented’ trial outcomes, bull rally

Next Article CVS, Humana dip amid new mental health pointers, Leerink note (NYSE:HUM)